You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 榮昌生物-B(9995.HK)反彈9% 首季營收超去年全年
格隆匯4月28日丨昨日創新低的榮昌生物-B(9995.HK)反彈9%,現報31.17港元,總市值166.8億港元。公司昨晚公吿,一季度收入1.50億元,超過21年全年的1.31億元。從披露的財報看,營收增長主要由注射用泰它西普、注射用維迪西妥單抗這兩款明星產品貢獻。由於研發投入持續加碼及商業化全面提速等因素,榮昌生物報吿期內歸屬於上市公司股東的淨利潤出現虧損。但考慮到公司兩大核心產品進入醫保後銷售迅速放量、研發管線拓展和國際化推進帶來“護城河”進一步夯實,榮昌生物首季表現依然可圈可點。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account